文献速递白血病造血干细胞移植与细胞治疗

奥加伊妥珠单抗治疗成人复发或难治性急性淋巴细胞白血病的肝脏不良事件特征:开放标签随机3期INO-VATE研究结果

Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.
PubMed 文献 · Lancet Haematol · 2017-07-04

INO-VATE研究比较奥加伊妥珠单抗与标准化疗在成人复发或难治性B细胞急性淋巴细胞白血病中的疗效与安全性。本预设安全性分析显示,奥加伊妥珠单抗组治疗期间出现的肝毒性(51% vs 34%)及肝窦阻塞综合征(13% vs <1%)均高于标准化疗组,尤其在接受后续造血干细胞移植后。多因素分析中,两种烷化剂预处理及移植前胆红素≥正常上限与肝窦阻塞综合征风险升高相关。

要点

  • 奥加伊妥珠单抗组治疗期间肝毒性发生率为51%,标准化疗组为34%。
  • 奥加伊妥珠单抗组肝窦阻塞综合征发生率为13%,标准化疗组为<1%。
  • 接受后续HSCT者中,奥加伊妥珠单抗组22%发生肝窦阻塞综合征,其中5例致死。

核心结论

  • 与标准化疗相比,奥加伊妥珠单抗治疗与肝毒性增加相关,尤其在后续造血干细胞移植后。

研究设计与样本

  • 开放标签、3期、多中心、国际随机研究,纳入复发或难治性CD22阳性Ph阳性或Ph阴性B细胞急性淋巴细胞白血病成人患者。
  • 患者按1:1随机接受奥加伊妥珠单抗(起始剂量1.8 mg/m2每周期,第1天0.8 mg/m2,第8天和第15天0.5 mg/m2,21-28天为一周期,最多6周期)或标准化疗(氟达拉滨+阿糖胞苷+粒细胞集落刺激因子、米托蒽醌+阿糖胞苷或大剂量阿糖胞苷)。
  • 随机分层因素为首次缓解持续时间(<12个月 vs ≥12个月)、挽救治疗阶段(首次 vs 第二次)和年龄(<55岁 vs ≥55岁)。
  • 安全性分析纳入至少接受一剂研究治疗的患者:奥加伊妥珠单抗组164例,标准化疗组143例。
  • 数据截止日期为2016年3月8日;长期随访已完成,末例患者末次访视为2017年1月4日。

主要发现

  • 治疗期间(或未行HSCT的随访期间)及治疗后并后续HSCT后,肝窦阻塞综合征复合事件在奥加伊妥珠单抗组为22例(13%),其中18例(82%)为3级或更严重;标准化疗组为1例(<1%)。
  • 研究治疗期间或未行HSCT的随访期间,奥加伊妥珠单抗组5例(3%)发生肝窦阻塞综合征,标准化疗组0例。
  • 接受奥加伊妥珠单抗并后续行HSCT的77例患者中,17例(22%)发生肝窦阻塞综合征,其中5例事件在后续HSCT后致死。
  • 接受标准化疗并后续行HSCT的32例患者中,1例(3%)发生非致死性肝窦阻塞综合征,该事件在因感染性休克死亡时仍在持续。
  • 多因素分析显示,两种烷化剂预处理(对比一种烷化剂,p=0.015)和末次可用的移植前胆红素浓度≥正常上限(对比<正常上限,p=0.009)与接受奥加伊妥珠单抗患者肝窦阻塞综合征风险增加相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The INO-VATE study demonstrated efficacy and safety of inotuzumab ozogamicin versus standard care in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Here, we report the frequency of, and potential risk factors for, hepatotoxicity in patients in this trial and after treatment and subsequent haemopoietic stem-cell transplantation (HSCT). METHODS: In this open-label, phase 3, multicentre, international study, adults with relapsed or refractory, CD22-positive, Philadelphia chromosome (Ph)-positive or Ph-negative B-cell acute lymphoblastic leukaemia who were due to receive first or second salvage treatment were randomly assigned (1:1) via an interactive voice response system to receive inotuzumab ozogamicin (starting dose 1·8 mg/m2 per cycle [0·8 mg/m2 on day 1; 0·5 mg/m2 on days 8 and 15 of a 21-28 day cycle for ≤6 cycles]) or standard care (either fludarabine plus cytarabine plus granulocyte colony-stimulating factor, mitoxantrone plus cytarabine, or high-dose cytarabine). Stratification factors at randomisation were duration of first remission (<12 months vs ≥12 months), salvage treatment phase (first vs second), and age (<55 years vs ≥55 years). We present data up to March 8, 2016. At this cutoff date, all patients had been discontinued from treatment but 54 patients were continuing in long-term follow-up. Long-term follow-up has now been completed, with the final patient's last visit on Jan 4, 2017. This prespecified safety analysis describes investigator-assessed treatment-emergent hepatotoxicity, including sinusoidal obstruction syndrome (also known as veno-occlusive disease) in patients during study treatment or thereafter (without follow-up HSCT) and after study treatment and subsequent HSCT, for all patients who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov, number NCT01564784. FINDINGS: Between Aug 27, 2012, and and the data cutoff of March 8, 2016, 326 patients were randomly assigned to receive inotuzumab ozogamicin (n=164) or standard care (n=162). 164 patients in the inotuzumab ozogamicin group and 143 in the standard care group received at least one dose of study treatment and were included in the safety population. At data cutoff, median duration of treatment (induction) was 8·9 weeks (IQR 4·1-13·1) in the inotuzumab ozogamicin group and 0·9 weeks (0·9-1·1) in the standard care group. Treatment-emergent hepatotoxicities (of all grades) were more frequent in the inotuzumab ozogamicin group (83 [51%] of 164 patients) than in the standard care group (49 [34%] of 143 patients). The frequency of sinusoidal obstruction syndrome-comprising events occurring during treatment (or follow-up without HSCT) and after treatment and subsequent HSCT-was higher in the inotuzumab ozogamicin group (22 [13%]; 18 [82%] of which were grade 3 or worse) than in the standard care group (one [<1%]). During study therapy or follow-up without HSCT, five (3%) patients in the inotuzumab ozogamicin group developed sinusoidal obstruction syndrome compared with no patients in the standard care group. Of the 77 patients who received inotuzumab ozogamicin and proceeded to HSCT, 17 (22%) had sinusoidal obstruction syndrome; five events after follow-up HSCT were fatal. Of 32 patients who received standard care and proceeded to HSCT, one (3%) had (non-fatal) sinusoidal obstruction syndrome that was ongoing at the time of death due to septic shock. In multivariate analysis, conditioning with two alkylating agents (p=0·015 vs one alkylating agent) and last available pre-HSCT bilirubin concentration of greater than or equal to the upper limit of normal (ULN; p=0·009 vs <ULN) were associated with increased risk of sinusoidal obstruction syndrome in patients who received inotuzumab ozogamicin. The estimated hazard ratio for overall survival in patients with follow-up HSCT (inotuzumab ozogamicin vs standard care) was 1·227 (97·5% CI 0·656-2·292; one-sided stratified log-rank p=0·77); at 24 months, the estimated probability of survival was 38·9% (95% CI 27·6-50·0) in the inotuzumab ozogamicin group versus 28·7% (11·2-49·1) in the standard care group. INTERPRETATION: Treatment with inotuzumab ozogamicin is associated with increased hepatotoxicity, especially after follow-up HSCT, compared with standard care. FUNDING: Pfizer.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Kantarjian HM, DeAngelo DJ, Advani AS, et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017. PMID: 28687420. doi:10.1016/S2352-3026(17)30103-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。